Alzheimer's Disease Research Center

阿尔茨海默病研究中心

• 批准号: 10461180
• 负责人: SUZANNE CRAFT
• 金额: $ 305.32万
• 依托单位: WAKE FOREST UNIVERSITY HEALTH SCIENCES
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-08-15 至 2026-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10461180
• 关键词: Address; Adult; African American; African American population; Age; Aging; Alzheimer' s Disease; Alzheimer' s disease risk; American; Amyloid; Area; Biological Markers; Blood Vessels; Capsicum; Clinical; Clinical Sciences; Clinical Trials; Cognition; Collaborations; Communities; Complex; Data; Dementia; Diabetes Mellitus; Disease; Doctor of Philosophy; Early Intervention; Ecosystem; Education; Elderly; Enrollment; Ensure; Epidemic; Faculty; Faculty Recruitment; Family; Family health status; Foundations; Functional disorder; Funding; General Population; Goals; Grant; Health Professional; Heterogeneity; High Prevalence; Human; Hypertension; Impaired cognition; Infrastructure; Institutes; Intervention Trial; Leadership; Magnetic Resonance Imaging; Medical; Metabolic; Metabolic Diseases; Methods; Mission; Modeling; Neurosciences; Participant; Patient Education; Patients; Phase Transition; Play; Positron-Emission Tomography; Prediabetes syndrome; Predictive Factor; Prevalence; Prevention; Prevention strategy; Publications; Reduce health disparities; Research; Research Activity; Research Infrastructure; Research Personnel; Resources; Risk; Risk Factors; Role; Sampling; Statistical Data Interpretation; Strategic Planning; Symptoms; Training; Translational Research; Underrepresented Populations; Vascular Diseases; Work; behavioral neurology; clinical center; clinical implementation; cohort; data management; disease heterogeneity; education research; experience; forest; health disparity; health equity; imaging biomarker; innovation; investigator training; medical schools; neuroimaging; neuropathology; nonhuman primate; normal aging; novel; novel strategies; outreach; prevent; preventive intervention; programs; recruit; repository; resilience; symptom treatment; tau Proteins; translational pipeline; vascular factor; vascular risk factor

Overall – Project Summary The Alzheimer’s Disease Research Center (ADRC) was founded at Wake Forest School of Medicine (WFSM) in 2016 to provide a comprehensive infrastructure for research on the pathophysiology, prevention, and treatment of AD and related disorders (ADRD). The theme of our ADRC is to better understand early transitions from normal aging to MCI and dementia, and to elucidate the role that metabolic and vascular factors play in these transitions, through coordinated research activities spanning the translational spectrum. No current therapies effectively prevent or treat the symptoms of AD. This chasm highlights the need to identify antecedent biomarkers and risk factors that predict later-life vulnerability or resilience, in order to develop strategies for prevention and early intervention. Metabolic and vascular disorders are powerful modifiable factors that may contribute to the transitions from normal aging to MCI and ADRD. Such disorders are epidemic in the Southeastern region surrounding the WF ADRC; more than 70% of adults over the age of 50 have prediabetes, diabetes, or hypertension. These disorders increase the risk of cognitive impairment and dementia through complex interactions that are poorly understood. The WF ADRC seeks to provide resources to better understand these interactions. We also seek to elucidate the multi-dimensional role that health disparities play in influencing risk for AD. We emphasize engagement of African Americans and other underrepresented groups, who are twice as likely to develop dementia, and have high rates of diabetes and vascular disease. To promote innovative research on metabolic/vascular risk and health disparities, our Outreach, Recruitment and Engagement and Clinical Cores have partnered to enroll and follow ~600 participants, carefully characterizing their vascular and glycemic status. Participants receive magnetic resonance imaging and amyloid and tau positron emission tomography overseen by the Imaging Biomarker Core. Valuable samples and data from this cohort are made widely available to the National Alzheimer’s Coordinating Center, the National Centralized Repository for AD and other investigators by the Data Management and Statistical Analysis and Neuropathology Cores, providing invaluable resources to address numerous National Alzheimer’s Project Act milestones. The Neuropathology Core has also characterized novel nonhuman primate models with methods that parallel the ADRC’s human cohort to promote translational research. Finally, the ADRC and its Research Education Component provide training relating to AD, metabolic/ vascular factors and health disparities to a diverse cadre of new researchers, and education for patients and families, health professionals, and the community. The prevalence of metabolic and vascular risk factors, their role in onset, progression, and heterogeneity of ADRDs, and the strengths of the WF ADRC in these research areas, ensure that we will make high-impact contributions to the search for strategies to treat and prevent AD.

总体--项目摘要 阿尔茨海默病研究中心(ADRC)成立于维克森林医学院(WFSM) 2016年，为病理生理学、预防和研究提供全面的基础设施 治疗阿尔茨海默病及相关疾病(ADRD)。我们ADRC的主题是更好地了解早期 从正常衰老到MCI和痴呆的转变，并阐明代谢和血管的作用 通过跨翻译领域的协调研究活动，因素在这些转变中发挥作用。 目前没有有效预防或治疗阿尔茨海默病症状的疗法。这一鸿沟突显了识别 预测晚年脆弱性或恢复力的先行生物标志物和风险因素，以便发展 预防和早期干预战略。代谢和血管疾病是强大的、可改变的 可能有助于从正常衰老向MCI和ADRD过渡的因素。这类障碍是 WF ADRC周围东南部地区的流行病；超过70%的50岁以上成年人 有糖尿病前期、糖尿病或高血压。这些障碍会增加认知障碍的风险，并 痴呆症是通过复杂的相互作用造成的，但人们对此知之甚少。WF ADRC寻求提供资源 以更好地理解这些相互作用。我们还试图阐明健康在多方面的作用 差异在影响AD风险方面发挥作用。我们强调非裔美国人和其他人的参与 代表不足的群体，他们患痴呆症的可能性是他们的两倍，糖尿病和 血管疾病。为了促进对代谢/血管风险和健康差距的创新研究，我们的 外展、招聘和接洽与临床核心合作，登记和跟踪约600人 参与者，仔细描述他们的血管和血糖状况。参与者收到磁铁 由成像生物标记物监测的共振成像和淀粉样蛋白和tau正电子发射断层扫描 核心。来自这个队列的有价值的样本和数据被广泛提供给国家阿尔茨海默氏症 协调中心，国家AD和其他调查人员的数据集中库 管理和统计分析以及神经病理学核心，提供了宝贵的资源来解决 许多国家阿尔茨海默氏症项目法案的里程碑。神经病理核心也是小说的特征 非人灵长类动物模型与ADRC的人类队列平行的方法，以促进翻译 研究。最后，ADRC及其研究教育部门提供与AD、代谢/ 向不同的新研究人员干部提供血管因素和健康差距，并对患者和 家庭、卫生专业人员和社区。代谢和血管危险因素的患病率，其 ADRD在发病、进展和异质性中的作用，以及WF ADRC在这些研究中的优势 在这些领域，确保我们将为寻求治疗和预防阿尔茨海默病的战略作出有重大影响的贡献。